Context sidebar
01.10.2020
The new Light procedure builds on the established MAGHP procedure, but is explicitly applicable to applications for the fast-track authorisation procedure and for temporary authorisation
18.09.2020
Publication of new guidance document on procedures for authorising medicinal products during a pandemic
15.09.2020
ZL000_00_022e_WL
01.09.2020
ZL000_00_047e_WL
18.08.2020
Swissmedic compared with the EMA and the FDA and analysis of the national authorisation procedures
01.08.2020
ZL000_00_024e_WL / ZL101_00_007e_WL
03.07.2020
In an international comparison of the processing time for scientific assessments, Swissmedic is on a par with the fastest authorities
01.07.2020
Swissmedic is changing its practice
Avoiding text review rounds
Type II variations now possible
01.06.2020
ZL000_00_027e_WL
28.05.2020
Extension of the transition period
26.05.2020
Tucatinib for the treatment of a particularly aggressive type of breast cancer reviewed in four months
13.05.2020
This approval in Switzerland paves the way for the approval and introduction in low- and middle-income countries
06.05.2020
ZL000_00_019e_WL
Allocation of ATC code for human medicinal products (excl. CHM) to Case Management (XLS, 265 kB, 01.09.2020)
Allocation of CHM to Case Management (XLS, 2 MB, 30.09.2020)
Top of page
